Payment overview · 2025
General Payments
$358.03
27 reported records · 8 companies
Healthcare provider profile · identity verified
James Boulware Gettys, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TRAVELERS REST, SC · NPI 1912940586
Verified facts
What the public records show
CMS Open Payments records show James Boulware Gettys, M.D. received $358.03 in general payments during 2025 across 27 reported records.
ABBVIE INC. accounted for 49.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $175.52 | 49.0% | 16 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $61.17 | 17.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.81 | 10.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.43 | 7.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.04 | 5.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.72 | 4.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.96 | 3.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.38 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $358.03 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $133.84 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $61.17 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.68 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.68 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.81 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 38 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 543 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 318 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 312 | 93 |
| Omeprazole | Omeprazole | 310 | 95 |
| Lisinopril | Lisinopril | 269 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 229 | 72 |
| Gabapentin | Gabapentin | 218 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 216 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 57 |
| Losartan Potassium | Losartan Potassium | 178 | 59 |
| Oxycodone Hcl | Oxycodone Hcl | 176 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 174 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 55 |
| Alprazolam | Alprazolam | 131 | 18 |
| Metformin Hcl | Metformin Hcl | 123 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 44 |
| Meloxicam | Meloxicam | 115 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 33 |
| Lorazepam | Lorazepam | 109 | 21 |
| Simvastatin | Simvastatin | 98 | 28 |
| Trazodone Hcl | Trazodone Hcl | 97 | 30 |
| Celecoxib | Celecoxib | 94 | 28 |
| Clonazepam | Clonazepam | 90 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 21 |
| Tramadol Hcl | Tramadol Hcl | 89 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 30 |
| Allopurinol | Allopurinol | 82 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 27 |
| Furosemide | Furosemide | 81 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 25 |
| Carvedilol | Carvedilol | 76 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 73 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 25 |
| Bupropion Xl | Bupropion Hcl | 69 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 24 |
| Sertraline Hcl | Sertraline Hcl | 69 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 67 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 66 | 22 |
| Spironolactone | Spironolactone | 63 | 23 |
| Famotidine | Famotidine | 62 | 21 |
| Temazepam | Temazepam | 62 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 26 |
| Ondansetron Odt | Ondansetron | 58 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 19 |
| Meclizine Hcl | Meclizine Hcl | 53 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | 16 |
| Naproxen | Naproxen | 52 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 18 |
| Ozempic | Semaglutide | 52 | suppressed |
| Pregabalin | Pregabalin | 51 | 17 |
| Alendronate Sodium | Alendronate Sodium | 47 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 13 |
| Donepezil Hcl | Donepezil Hcl | 44 | 14 |
| Eliquis | Apixaban | 44 | 14 |
| Eszopiclone | Eszopiclone | 44 | 17 |
| Ezetimibe | Ezetimibe | 43 | 13 |
| Finasteride | Finasteride | 43 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 19 |
| Mirtazapine | Mirtazapine | 41 | 16 |
| Farxiga | Dapagliflozin Propanediol | 39 | 13 |
| Jardiance | Empagliflozin | 38 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 14 |
| Prednisone | Prednisone | 37 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 18 |
| Diazepam | Diazepam | 35 | suppressed |
| Baclofen | Baclofen | 33 | 12 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Estradiol | Estradiol | 27 | 13 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 20 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 14 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $358.03 · 27 records | ABBVIE INC. | CAPLYTA, JARDIANCE, MOUNJARO, Ozempic, QULIPTA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error